Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms ...

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...

ZEN.L Zenith Energy Ltd.

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

At Sonida Senior Living, a filing with the SEC revealed that on Friday, Michael Simanovsky bought 42,111 shares of SNDA, at a cost of $21.32 each, for a total investment of $897,835. So far ...

India's electronics, solar and electric vehicle sectors are struggling to obtain essential high-tech machinery due to China's recent halt in exports. This move aims to impede manufacturing growth in ...

In December 2024, Intra-Cellular Therapies announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for CAPLYTA ® as an adjunctive ...

also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA ® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA ® has potential to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Acquisition includes CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of ...

The FDA accepted the revised sNDA for IZERVAY, addressing a previous Complete Response Letter from November 2024. The resubmission is classified as Class 1, with a 60-day review period, targeting a ...